폐암 환자의 폐절제술 후 발생한 급성 폐손상에서 호중구 Elastase 억제제 효과에 대한 예비연구
Effect of the Neutrophil Elastase Inhibitor on Acute Lung Injury after Pulmonary Resection for Lung Cancer: A Preliminary Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the leading causes of death after lungresection. Neutrophil elastase is thought to be an important mediator in the pathogenesis of ALI. Sivelestat is a new neutrophil elastase inhibitor which may improve the outcome in patients with ALI/ARDS after lung resection. The objective of this study was to determine whether or not sivelestat can reduce mortality in patients with ALI after pulmonary resection for lung cancer. Methods: This study was a retrospective case-control study of twenty three patients who developed ALI/ARDS within seven days of lung resection for lung cancer. The control group (n=12) received standard care, while the sivelestat group (n=11) received a continuous infusion of sivelestat (0.2 mg/kg/hr) for seven days in addition to standard care. Results: There was no significant difference in the baseline characteristics between the control and sivelestat groups, except for heart rate. Six of twelve patients (50%) in the control group survived, while seven of twelve patients (64%) survived in the sivelestat group (p=0.34). There was also no significant difference between the two groups in the progression to ARDS. In the sivelelestat group, survivors had lower APACHE II and SOFA scores than the patients in the control group. Conclusions: There was no additional effect of a neutrophil elastase inhibitor in the treatment of ALI after pulmonary resection for lung cancer.
Abstract
Background: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the leading causes of death after lungresection. Neutrophil elastase is thought to be an important mediator in the pathogenesis of ALI. Sivelestat is a new neutrophil elastase inhibitor which may improve the outcome in patients with ALI/ARDS after lung resection. The objective of this study was to determine whether or not sivelestat can reduce mortality in patients with ALI after pulmonary resection for lung cancer. Methods: This study was a retrospective case-control study of twenty three patients who developed ALI/ARDS within seven days of lung resection for lung cancer. The control group (n=12) received standard care, while the sivelestat group (n=11) received a continuous infusion of sivelestat (0.2 mg/kg/hr) for seven days in addition to standard care. Results: There was no significant difference in the baseline characteristics between the control and sivelestat groups, except for heart rate. Six of twelve patients (50%) in the control group survived, while seven of twelve patients (64%) survived in the sivelestat group (p=0.34). There was also no significant difference between the two groups in the progression to ARDS. In the sivelelestat group, survivors had lower APACHE II and SOFA scores than the patients in the control group. Conclusions: There was no additional effect of a neutrophil elastase inhibitor in the treatment of ALI after pulmonary resection for lung cancer.
참고문헌 (16)
- Grichnik KP, "Acute lung injury and acute respiratory distress syndrome after pulmonary resection", Semin Cardiothorac Vasc Anesth, 8, pp.317~334 (2004)
- Kutlu CA, "Acute lung injury and acute respiratory distress syndrome after pulmonary resection", Ann Thorac Surg, 69, pp.376~380 (2000)
- Jordan S, "The pathogenesis of lung injury following pulmonary resection", Eur Respir J, 15, pp.790~799 (2000)
- Kawabata K, "The role of neutrophil elastase in acute lung injury", Eur J Pharmacol, 451, pp.1~10 (2002)
- Moraes TJ, "Proteases and lung injury", Crit Care Med, 31(4), pp.S189~S194 (2003)
- Ware LB, "The acute respiratory distress syndrome", N Eng J Med, 342, pp.1334~1349 (2000)
- Kawabata K, "ONO-5046, a novel inhibitor of human neutrophil elastase", Biochem Biophys Res Commun, 177, pp.814~820 (1991)
- Tamakura S, "A phase III clinical study of neutrophil elastase inhibitor ONO-5046 Na in SIRS patients", J Clin Ther Med, 14, pp.289~318 (1998)
- Hoshi K, "Sivelestat, a neutrophil elastase inhibitor, reduces mortality rate of critically ill patients", Tohoku J Exp Med, 207, pp.143~148 (2005)
- Zeiher BG, "Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study", Crit Care Med, 32, pp.1695~1702 (2004)
- Bernard GR, "The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination", Am J Respir Crit Care Med, 149, pp.818~824 (1994)
- Minne L, "Evaluation of SOFAbased models for predicting mortality in the ICU: a systematic review", Critical Care, 12, pp.R161~ (2008)
- Shinsuke Sato, "Clinical evaluation to predict effectiveness of sivelestat sodium hydrate for postoperative acute lung injury by APACH II score", Surgery Journal, 2, pp.14~18 (2007)
- Kutlu CA, "Acute lung injury and acute respiratory distress syndrome after pulmonary resection", Ann Tthorac Surg, 69, pp.376~380 (2000)
- Kawabata K, "Delayed neutrophil elastase inhibition prevents subsequent progression of acute lung injury induced by endotoxin inhalation in hamsters", Am J Respir Crit Care Med, 161, pp.2013~2018 (2000)
- Zeiher BG, "Neutrophil elastase and acute lung injury: prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics", Crit Care Med, 30(5), pp.S281~S287 (2002)